EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure


American Journal of Medicine 74(6b): 61-72
New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure
Although nitrates produce marked decreases in ventricular filling pressures in patients with severe heart failure, their therapeutic value has long been believed to be limited because they were thought to exert minimal arterial dilating effects. Recently, however, new conceptual approaches to vasodilator drugs have been developed that have challenged this traditional view. These new perspectives indicate that nitrates exert dilator actions on both the arterial and venous circulations, and reduce both preload and afterload; such balanced circulatory responses are particularly evident when large doses of these drugs are used. Cardiac output increases markedly with nitrates in patients with a greatly increased systemic vascular resistance before treatment or with significant mitral regurgitation. The major reason for the limited increases in cardiac output noted in previous studies is the inclusion of patients with heart failure whose pretreatment values for cardiac output were within normal limits; in these persons nitrates markedly activate neurohumoral vasoconstrictor mechanisms that counteract the arterial dilating actions of these drugs. Long-term nitrate therapy attenuates exercise-induced increases in pulmonary venous pressures, which permit patients to undergo repeated submaximal exercise with fewer symptoms; this improves physical conditioning and exercise capacity, even in the absence of drug-related changes in cardiac output. The long-term hemodynamic and clinical benefits of nitrates in heart failure have been confirmed by two independent randomized double-blind placebo-controlled clinical trials.


Accession: 043745015

PMID: 6859073

DOI: 10.1016/0002-9343(83)90856-2



Related references

Nitrates and other peripheral vasodilator agents in acute myocardial infarct and congestive heart failure. Kardiologia Polska 21(1): 75-82, 1978

Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent. American Journal of Medicine 76(6a): 3-13, 1984

Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. American Journal of Cardiology 40(5): 794-801, 1977

Therapeutic strategies in congestive heart failure and the new inotrope-vasodilator agents. Western Journal of Medicine 142(2): 235-244, 1985

Vasodilator agents in chronic heart failure. Danish Medical Bulletin 30 Suppl 1: 1-9, 1983

Therapy of chronic heart failure with vasodilator agents. Der Internist 27(5): 315-321, 1986

Vasodilator agents in chronic heart failure: which is the best option?. Revista Medica de Chile 121(1): 81-88, 1993

Effect of vasodilator agents in chronic heart failure. Medizinische Klinik 76(9): 249-253, 1981

Application of vasodilator and positive inotropic agents in the treatment of heart failure. Zhonghua Yi Xue Za Zhi 63(11): 705-708, 1983

Combination vasodilator therapy for severe chronic congestive heart failure. Annals of Internal Medicine 85(4): 467-470, 1976